Penumbra Valuation
Is PEN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PEN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PEN * (MX$4109.28) is trading above our estimate of fair value (MX$1114.54)
Significantly Below Fair Value: PEN * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PEN *?
Key metric: As PEN * is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PEN *'s PS Ratio? | |
|---|---|
| PS Ratio | 8.1x |
| Sales | US$1.16b |
| Market Cap | US$9.40b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8x |
| Enterprise Value/EBITDA | 91x |
| PEG Ratio | 6.1x |
Price to Sales Ratio vs Peers
How does PEN *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
MASI Masimo | 4.5x | 6.0% | US$9.3b |
DEMANT Demant | 2.5x | 6.1% | DKK 58.0b |
COH Cochlear | 8.7x | 8.1% | AU$19.5b |
TFX Teleflex | 2.9x | 5.2% | US$8.9b |
PEN * Penumbra | 8.1x | 12.4% | Mex$9.4b |
Price-To-Sales vs Peers: PEN * is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (4.7x).
Price to Sales Ratio vs Industry
How does PEN *'s PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 135 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 135 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: PEN * is expensive based on its Price-To-Sales Ratio (8.1x) compared to the Global Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is PEN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PEN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.